KORU Medical Systems Reports Strong 2025 Growth, Positive Adjusted EBITDA, and Optimistic 2026 Guidance
KRMD has more than doubled off its 52-week low of $1.86.
Summary
KORU Medical Systems announced robust 2025 financial results, including 22.2% revenue growth and a significant reduction in net loss, alongside a positive shift to adjusted EBITDA and optimistic 2026 guidance for continued growth and positive cash flow.
Key Events · Earnings and Guidance · KRMD
-
Strong 2025 Financial Performance
Full year 2025 net revenues grew 22.2% to $41.1 million, with a 57% reduction in net loss to ($2.6) million.
-
Shift to Positive Adjusted EBITDA
The company achieved positive adjusted EBITDA of $0.6 million for the full year 2025, a 124% increase from the prior year.
-
Optimistic 2026 Guidance
KORU Medical initiated 2026 guidance projecting net revenue growth of 15-22% ($47.5 - $50.0 million), along with positive adjusted EBITDA and positive cash flow.
-
Strategic Product & Pipeline Expansion
Received 510(k) clearance for UCB RYSTIGGO®, achieved Freedom60® EU MDR certification, and announced two new pharmaceutical collaborations.
Analysis · KRMD · Industrial Applications And Services
This 8-K, furnishing the press release for the full year and fourth quarter 2025 results, signals a significant positive turning point for KORU Medical Systems. The company achieved strong revenue growth of 22.2% for the full year 2025 and substantially reduced its net loss by 57%. Critically, KORU Medical transitioned to positive adjusted EBITDA and projects positive cash flow for the full year 2026, indicating improved financial health and a clearer path to sustainable profitability. Additionally, strategic product developments, including 510(k) clearance for UCB RYSTIGGO® and new pharmaceutical collaborations, broaden the company's market reach and future growth opportunities. Investors should view these results and guidance as a strong indicator of operational execution and future potential.
At the time of this filing, KRMD was trading at $4.10 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $199.7M. The 52-week trading range was $1.86 to $6.61. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.